SUNPHARMA.NS
SUNPHARMA.NS
INE044A01036
SUN PHARMACEUTICAL IND L
Loading chart...

Company Profile

Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It also provides generic medications, such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids; specialty medications; antiretrovirals medications; and over-the-counter products, such as vitamins, analgesics, digestives, and lifestyle. In addition, the company offers generics and APIs for anti-cancers, peptides, steroids, sex hormones, immunosuppressant drugs, and controlled substances. Sun Pharmaceutical Industries Limited was founded in 1983 and is headquartered in Mumbai, India.

Related stocks

DIVISLAB.NS
DIVISLAB.NS • India
DIVI S LABORATORIES LTD
9,340 INR
25.62B USD 1Y +52.3%
TORNTPHARM.NS
TORNTPHARM.NS • India
TORRENT PHARMACEUTICALS L
4,656.9 INR
18.3B USD 1Y +29.4%
600276.SS
600276.SS • China
JIANGSU HENGRUI PHARMACEUTICALS
46.85 CNY
46.53B USD 1Y -34.2%
1276.HK
1276.HK • China
HENGRUI PHARMA
48 HKD
40.6B USD 1Y -45.3%
TAK
TAK • Japan
Takeda Pharmaceutical Company L
18.73 USD
59.83B USD 1Y +29.4%
4502.T
4502.T • Japan
TAKEDA PHARMACEUTICAL CO LTD
5,843 JPY
58.98B USD 1Y +34.8%
CIPLA.NS
CIPLA.NS • India
CIPLA LTD
1,301 INR
10.86B USD 1Y -14%
RDY
RDY • India
Dr. Reddy's Laboratories Ltd
12.48 USD
10.4B USD 1Y -12.8%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

5/7 Elevated
5Y Volatility
19.9% p.a.
Max Drawdown (5Y)
-19.8%
Sharpe Ratio (5Y)
0.70
Beta Factor
0.14
Size Class
Mega Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Historical Stress Test: Maximum peak-to-trough drawdown of -57.0% in the extended horizon.
ende